Pseudomonas aeruginosa

Overview

Pseudomonas aeruginosa is a Gram-negative bacterium and a major opportunistic pathogen of clinical importance. It is widely recognized for its intrinsic and acquired antimicrobial resistance, its ability to form biofilms, and its persistence in hospital and community settings. These traits make it a frequent cause of difficult-to-treat infections, particularly in intensive care units, burn and wound infections, chronic lung disease, and other settings where host defenses are compromised.

Biologically, P. aeruginosa is notable for its adaptability to hostile environments, including antibiotic exposure, mechanical confinement, and polymicrobial communities. Recent studies highlighted in the provided contexts emphasize its role as a carbapenem-resistant and multidrug-resistant pathogen, its involvement in chronic cystic fibrosis lung infection, and its capacity to co-colonize with organisms such as Staphylococcus aureus, Candida albicans, Escherichia coli, Acinetobacter baumannii, and Haemophilus influenzae. Because of these features, it is a major target for research into biofilm disruption, quorum sensing inhibition, novel antimicrobials, wound dressings, nanomaterials, and improved diagnostic assays.

Recent Publications Summary

Recent studies on Pseudomonas aeruginosa have focused heavily on infection control, wound healing, and rapid detection in clinically relevant settings. In diabetic and burn wound models, P. aeruginosa was frequently isolated and used as a key target for evaluating antimicrobial materials, including green-synthesized silver nanoparticles, triple-responsive hydrogels, programmable core-shell microneedle patches, and a Ru-based nanocomposite hydrogel. These approaches reported strong antibacterial effects, with silver nanoparticles showing the highest antibacterial and antibiofilm activity among tested nanomaterials against diabetic foot ulcer-associated bacteria, including P. aeruginosa, and rapid killing activity exceeding 10 log10 CFU/mL reduction within hours 42297939Jun. Similarly, the Ru-based hydrogel achieved over 99.9% eradication of P. aeruginosa under near-infrared irradiation, while the core-shell microneedle patch and the rosmarinic acid–cerium nanoparticle hydrogel both reported high inhibition or eradication of P. aeruginosa in infected wound contexts 42300215Jun42235776Jun42084863May. An AI-guided 3D-bioprinted chitosan methacrylate hydrogel also showed synergistic antibacterial activity against P. aeruginosa in vitro as part of a personalized diabetic ulcer repair strategy 42097229May.

Several publications examined natural products and plant-derived antimicrobials as anti-P. aeruginosa agents. Goldenberry juice reduced P. aeruginosa growth by 1–3 log CFU/mL in broth and milk systems, while essential oils from Thymus vulgaris, Rosmarinus officinalis, and Lavandula angustifolia reduced viability, biofilm biomass, and metabolic activity, with T. vulgaris oil removing P. aeruginosa biofilms at 2× MIC 42463768Jul42332877Jun. Ocimum basilicum varieties also showed antibacterial activity against P. aeruginosa, with the Genovese variety exhibiting stronger effects than the basilicum variety 42185519May. Additional studies identified kaempferide from Alpinia officinarum as a potent anti-P. aeruginosa compound with bacteriostatic and bactericidal activity, and a nutmeg-derived anti-quorum sensing molecule that was confirmed to act against P. aeruginosa 41666626Feb41936120Apr. Horseradish was likewise investigated as a source of quorum sensing inhibitors to attenuate P. aeruginosa virulence 41698559Feb.

Other work emphasized resistance, tolerance, and within-host evolution. A longitudinal genomic study showed that P. aeruginosa populations from six patients accumulated mutations during antimicrobial treatment, including changes in ampC, ftsI, and mexR, with increasing resistance over time 41837616Mar. In a separate mechanistic study, growth in confined elastic materials promoted P. aeruginosa tolerance to antibiotics in a stiffness-dependent manner, involving sodium-proton Sha antiporters and membrane remodeling 42213750May. A Tunisian ICU surveillance study reported that P. aeruginosa accounted for 21.1% of clinical isolates, with substantial resistance to ticarcillin, ceftazidime, imipenem, amikacin, ciprofloxacin, ceftazidime-avibactam, and ceftolozane-tazobactam, and 30.7% of isolates were multidrug-resistant 41806369Mar. In diabetic wound infection surveillance from Iraq, P. aeruginosa was isolated in 44.68% of wound swabs, and occupational status and overweight were among the factors associated with infection in multivariable analysis 42497179Jul.

Detection and diagnostic platforms also featured prominently. A machine learning-assisted immunoassay platform using a trimetallic nanozyme was developed for ultrasensitive detection of P. aeruginosa 42246701Jun. A multiplex lateral flow immunoassay incorporating magnetic fluorescent probes enabled concurrent detection of P. aeruginosa alongside procalcitonin and interleukin-6 for bedside sepsis diagnosis, with a reported detection limit of 7 CFU/mL for the bacterium 42237556Jun. Together, these publications portray P. aeruginosa as a major target in studies spanning antimicrobial discovery, biofilm disruption, wound therapy, resistance evolution, and point-of-care diagnostics.

What Changes, What Holds

1. Wound-focused antimicrobial materials extend the therapeutic toolkit against P. aeruginosa without changing its core role as a hard-to-treat pathogen
REINFORCES These studies sharpen the baseline view of P. aeruginosa as a major target in biofilm disruption and wound-infection research. The main change is practical rather than conceptual: multiple engineered hydrogels, microneedles, and nanoparticles are being positioned as high-potency local therapies for infected diabetic and burn wounds, but that fits the established picture of a resilient, biofilm-forming opportunist. 42297939Jun42300215Jun

2. Natural products are emerging as adjunct anti-virulence and anti-biofilm options against P. aeruginosa
REINFORCES The new work broadens the menu of candidate inhibitors, but it does not alter the baseline understanding that P. aeruginosa is a frequent target for antimicrobial discovery and quorum-sensing interference. What matters is the growing emphasis on reducing growth, biofilm biomass, and virulence rather than replacing conventional therapy outright. The evidence is still largely screening- and model-based, so clinical relevance remains unsettled. 42463768Jul42332877Jun

3. Resistance continues to intensify during treatment and in confined environments
REINFORCES These findings strengthen, rather than challenge, the established account of P. aeruginosa as intrinsically and adaptively drug resistant. The longitudinal mutation data and the stiffness-dependent tolerance work add mechanistic detail to a known problem: therapy can select for further resistance, and physical confinement can make antibiotics less effective. The ICU and wound-surveillance data also fit the baseline’s emphasis on difficult-to-treat infections. 41837616Mar42213750May

4. Rapid multiplex detection is becoming a more practical use case for P. aeruginosa diagnostics
METHOD The new assays change how P. aeruginosa is measured, not what it is known to do. They extend the baseline’s mention of improved diagnostic assays by showing that machine learning, nanozymes, and multiplex lateral flow formats can push detection toward bedside and sepsis workflows. The consequence is better point-of-care usability, while the underlying clinical significance of detecting the organism remains the same. 42246701Jun42237556Jun

Overview update candidates: wound-directed nanomaterials and hydrogels as prominent anti-P. aeruginosa strategies; natural-product anti-biofilm and anti-quorum-sensing candidates; confinement-driven antibiotic tolerance as a mechanistic contributor to resistance; multiplex point-of-care detection platforms.